# GlycoEra

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glycoera

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.glycoera.com
- Total disclosed funding: $179M
- Latest round: Series B (May 17, 2025)
- Investors on record: 13

## About

Founded in 2020 by Amir Faridmoayer, Dominique N. Sirena, and Veronica Gambillara Fonck, and based in Zürich, Switzerland operates a glycoengineering platform to develop a pipeline of biologics for the treatment of autoimmune and other diseases. In May 2025, GlycoEra AG raised USD 130 million in series B funding led by Novo Holdings, with participation from Catalio Capital Management, LifeArc, Qatar Investment Authority, Agent Capital, MP Healthcare Venture Management, Sixty Degree Capital, Sofinnova Partners, 5AM Ventures, Roche Venture Fund, Bristol-Myers Squibb Company, and other unspecified investors. GlycoEra specializes in precision immunology, focusing on biologics designed to selectively degrade disease-driving proteins, particularly autoantibodies in autoimmune disorders. The platform uses a novel approach to target and degrade specific extracellular proteins, enabling early intervention with potentially improved safety and effectiveness compared to broad-spectrum therapies. GlycoEra’s technology aims to enhance patient outcomes by providing targeted treatments for various diseases, including autoimmune conditions, with applications also in oncology, neurology, and infectious diseases. The company will use the May 2025 funding to advance the development of its extracellular protein degraders for autoimmune diseases.

## Funding rounds

- Series B, May 17, 2025, $130M — Sofinnova Partners, 5AM Ventures, Novo Holdings, Qatar Investment Authority, Bristol-Myers Squibb Company, Roche Venture Fund, MP Healthcare Venture Management, Agent Capital, Catalio Capital Management, Sixty Degree Capital, LifeArc
- Series A, Jan 5, 2024 — Sofinnova Partners, 5AM Ventures, Roche Venture Fund, Bristol-Myers Squibb Company's diabetes alliance
- Series A, Nov 4, 2021, $49M — Sofinnova Partners, 5AM Ventures, Roche Venture Fund, LimmaTech Biologics AG

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- LimmaTech Biologics AG — Series A
- Bristol-Myers Squibb Company's diabetes alliance — Series A
- Novo Holdings — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- Bristol-Myers Squibb Company — Series B
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series B
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Series B